Please use this identifier to cite or link to this item: doi:10.22028/D291-35779
Title: Intravitreal aflibercept following treat and extend protocol versus fixed protocol for treatment of neovascular age-related macular degeneration
Author(s): Abdin, Alaa Din
Mohamed, Asem
Munteanu, Cristian
Weinstein, Isabel
Langenbucher, Achim
Seitz, Berthold
Suffo, Shady
Language: English
Title: International Journal of Retina and Vitreous
Volume: 7
Issue: 1
Publisher/Platform: BMC
Year of Publication: 2021
Free key words: Neovascular age-related macular degeneration
Treat and extend
Fixed protocol
DDC notations: 610 Medicine and health
Publikation type: Journal Article
Abstract: Background To assess the morphological and functional outcome of intravitreal aflibercept following the treat and extend protocol compared to the fixed protocol for treatment of eyes with neovascular age-related macular degeneration. Methods This retrospective study included 126 eyes of 113 patients with primary onset neovascular age-related macular degeneration who were followed for 12 months. All eyes were treated with 2 mg/0.05 mL aflibercept. All eyes received an upload with three monthly aflibercept injections. We subsequently studied two groups of eyes. For group 1, 54 eyes were treated following the treat and extend protocol. For group 2, 72 eyes were treated following the fixed protocol (fixed 2-monthly interval). Main outcome measures included: best corrected visual acuity (BCVA), central macular thickness (CMT) and number of injections. Results BCVA (logMAR) in group 1 vs group 2 was (0.61 ± 0.3 vs 0.72 ± 0.3, p = 0.09) before treatment and (0.48 ± 0.3 vs 0.51 ± 0.3, p = 0.6) after one year of treatment. CMT in group 1 vs group 2 was (371 ± 101 μm vs 393 ± 116 μm, p = 0.5) before treatment and (284 ± 60 μm vs 290 ± 67 μm, p = 0.1) after one year of treatment. Number of injections/eye in group 1 vs group 2 was (8.5 ± 2.2 vs 7.0 ± 0, p < 0.001). Conclusions Significant differences regarding BCVA and central macular thickness were not found between both treatment protocols during the first year of treatment using aflibercept. However, a significantly higher number of injections was needed for eyes in the treat and extend group during the first year of treatment. This might suggest that aflibercept should better not be extended past an 8 weeks interval during the first year of treatment. Study registration This study was approved by the Ethics Committee of the Medical Association of Saarland, Germany (Nr. 123/20, Date: 16.06.2020). All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This article does not contain any studies with animals performed by any of the authors.
DOI of the first publication: 10.1186/s40942-021-00349-x
Link to this record: urn:nbn:de:bsz:291--ds-357798
ISSN: 2056-9920
Date of registration: 17-Mar-2022
Faculty: M - Medizinische Fakultät
Department: M - Augenheilkunde
Professorship: M - Univ.-Prof. Dr. Dipl.-Ing. Achim Langenbucher
M - Prof. Dr. Berthold Seitz
Collections:SciDok - Der Wissenschaftsserver der Universität des Saarlandes

Files for this record:
File Description SizeFormat 
Abdin2021_Article_IntravitrealAfliberceptFollowi.pdf941,31 kBAdobe PDFView/Open

This item is licensed under a Creative Commons License Creative Commons